An interventional study of Continuous glucose monitoring and health coaching and EMPOWER mobile app in Diabetes Mellitus, Type 2, sponsored by Singapore General Hospital. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-17.
Sponsored by Singapore General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital — 5 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Singapore General Hospital.
Among the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 12th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →5 of the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital are open now, in 1 country. Recruiting first, the newest first:
Singapore General Hospital · Sites in Singapore
Ages 21–100
Singapore General Hospital · Sites in Singapore
Ages 21+
Singapore General Hospital · Sites in Singapore
Ages 40–75
Singapore General Hospital · Sites in Singapore
Ages 21–70
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 21 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 400 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 150 across the 13 interventional studies, 386 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lifestyle change is key to diabetes management but there are limited resources and time to support patients in improving lifestyle behaviour in the current healthcare system. Currently, health coaching for behavioural chance guided by continuous glucose data, wearable and lifestyle data is not available in primary and tertiary care management of diabetes. This parallel-group randomised controlled trial (RCT) aims to investigate the effectiveness of a novel multi-component model of care comprising interventions including the mobile app EMPOWER and smartwatch, health coaching, and continuous glucose monitoring (CGM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Continuous glucose monitoring and health coaching · Behavioral: EMPOWER mobile app
Behavioral: EMPOWER mobile app
Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial. Participants will interact with health coach throughout the study duration.
Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
HbA1c
HbA1c over 6 months
Time frame: 6 months
Physical activity as measured by number of steps
Physical activity over 6 months
Time frame: 6 months
Physical activity as measured by moderate to vigorous active minutes
Physical activity over 6 months
Time frame: 6 months
Physical activity as measured by GPAQ
Physical activity over 6 months
Time frame: 6 months
Diet as measured by DASH
Diet quality over 6 months
Time frame: 6 months
Sugar sweetened beverages intake
Sugar sweetened beverages intake over 6 months
Time frame: 6 months
Patient activation score as measured by patient activation measure
Difference in patient activation score between intervention and control over 6 months
Time frame: 6 months
Medication adherence as measured by DOSE-Nonadherence scale
Difference in medication adherence between intervention and control over 6 months
Time frame: 6 months
Quality of life as measured by EQ-5D-5L
Difference in quality of life between intervention and control over 6 months
Time frame: 6 months
Healthcare cost as measured by cost of consultations, lab tests, medications, admission
Healthcare cost over 6 months
Time frame: 6 months
Healthcare cost as measured by WPAI
Healthcare cost over 6 months
Time frame: 6 months
Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 14 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.